Alex Mullen

Alex Mullen is the Founder and Chief Scientific Officer at Fitabeo Therapeutics, a spin-out from the University of Strathclyde, established in October 2022, specializing in thin films for oral drug delivery. With over 10 years of research backing the venture, Fitabeo Therapeutics offers licensable technologies for targeted sublingual, buccal, and oral delivery. Concurrently, Alex serves as a Professor of Pharmacy Practice at the University of Strathclyde since April 2008. Previous experience includes the role of Chief Scientific Officer at BDD Pharma from February 2011 to September 2022, focusing on pharmaceutical development and controlled release technologies, and a similar position at Drug Delivery International, specializing in various drug delivery forms. Alex's career began as a Formulation Scientist at Reckitt & Colman in 1991. Educational qualifications include a PhD in Pharmaceutical Sciences and a BSc in Pharmacy from the University of Strathclyde, along with a Postgraduate Certificate in Education.